leisure time -WSS

leisure time

author：comprehensive 2025-09-27 09:54:58 - browse：8155

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Baby aspirin cuts fat buildup in liver disease patients, in small study

entertainment

WSS

Health AI adoption puts security, privacy startups on investors' radar

First over

Why Talkspace is targeting Medicare, a tricky market

For AI in health care standards, federal regulators join with industry group

Nurses recount patients attacks

Methadone treatment changes are coming. Do they go far enough?

focus

leisure time

hotspot

Psychedelics group wrestles with new pharma identity

Stop the failed accountable care organization experiment

Apple is now the first public company to be valued at $3 trillion

5 to watch: Tech startups trying to solve health care's staffing crisis

Cancer drug shortages should be causing more outrage

Physicians and social media: If you see something, say something?

Cancer drug shortages should be causing more outrage

Virtual Event: March of the Biosimilars

Cancer drug shortages should be causing more outrage

Stop the failed accountable care organization experiment

focus

The public health thinking behind the CDC’s new Covid guidance

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Physicians and social media: If you see something, say something?

Baby aspirin cuts fat buildup in liver disease patients, in small study

The public health thinking behind the CDC’s new Covid guidance

entertainment

explore

hotspot

hotspot